With few treatments available to treat Alzheimer’s disease, scientists have turned to cancer drugs as a potential means of ...

Scientists at UCSF and Gladstone Institutes have identified cancer drugs that promise to reverse the changes that occur in ...

ProMIS Neurosciences Inc. (Nasdaq:PMN), a clinical-stage biotechnology firm specializing in treatments for neurodegenerative ...

ProMIS Neurosciences shares surged after the company said the Food and Drug Administration granted a fast-track designation to the company's in-development treatment for Alzheimer's disease. Shares ...

The phase 1b PRECISE-AD trial is currently investigating PMN310 in patients with mild cognitive impairment due to AD and in those with mild AD.

TWO NHS drugs could be combined to treat, and even reverse, the most common form of dementia, scientists claim. A pair of ...

Unlike expensive positron emission tomography (PET) scans or invasive lumbar punctures, the new blood test measures the ratio ...

The Food and Drug Administration on Monday approved a high-profile Alzheimer's drug, a controversial decision to green light the first new drug to slow the mind-robbing disease in nearly two decades.

FDA approval comes after controversy over other Alzheimer's drug, Aduhelm The decision to approve lecanemab came after last week's scathing congressional report on high-profile Aduhelm.. In an 18 ...

An Alzheimer's drug that removes the substance amyloid from the brain has received a conditional approval from the FDA. A large study found the drug decreased the loss of thinking and memory by 27%.

The U.S. Food and Drug Administration (FDA) has approved a new medication for people with Alzheimer’s disease. Eli Lilly’s Kisunla (donanemab) is a once-monthly injection intended for adults ...

An experimental Alzheimer’s drug, donanemab, was endorsed by a U.S. Food and Drug Administration (FDA) advisory panel on Monday. Donanemab is designed to treat symptoms of early Alzheimer’s ...